Blinatumomab: Cytokine release syndrome.

In a study involving 20 adult patients, one patient developed cytokine release syndrome while receiving blinatumomab as bridge therapy for B-Cell acute lymphoblastic leukemia. The patient had a low leukemia burden and started receiving blinatumomab at a dose of 8 µg/day, which was gradually increased to 28 µg/day over 5-10 days. The patient experienced grade 2 cytokine release syndrome and later underwent allogeneic hematopoietic stem cell transplantation. [Extracted from the article]